2-Butyl-5-methyl-[1,3,4]oxadiazole | 189569-99-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Butyl-5-methyl-[1,3,4]oxadiazole
• 英文别名: 2-Butyl-5-methyl-1,3,4-oxadiazole
• CAS: 189569-99-1
• 化学式: C₇H₁₂N₂O
• 分子量: 140.185
• InChiKey: UPQRXUXRLRHVSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  戊酸肼 、 (三苯基膦烯)乙烯酮 在 苯甲酸 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 以50%的产率得到2-Butyl-5-methyl-[1,3,4]oxadiazole
  参考文献：
  名称：

  Synthesis of 1,3,4-Oxadiazoles from Carboxylic Hydrazides and of 1,2-Oxazin-6-ones from α-(Hydroxyimino)carboxylic Esters with Keteneylidene Triphenylphosphorane

  摘要：

  在一锅法操作中，1,3,4-恶二唑8由羧酸酰肼2和烯酮叶立德三苯基膦1通过非典型的分子间维蒂希烯烃化反应制备，该反应涉及氨基甲酸酯型的羰基。在类似条件下，1与α-(羟基亚氨基)羧酸酯9反应，通过包括分子内烯烃化步骤的不同过程生成1,2-恶嗪-6-酮11。

  DOI：

  10.1055/s-1997-766

文献信息

• [EN] 2,7-DIAZASPIRO[4.4]NONANES<br/>[FR] 2,7-DIAZASPIRO [4,4] NONANES
  申请人：BAYER AG

  公开号：WO2018024602A1

  公开（公告）日：2018-02-08

  The present invention covers 2,7-diazaspiro[4.4]nonane compounds of general formula (I): in which n, X, R2, R3, R4, R5, R6a and R6b are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or diabetes, as a sole agent or in combination with other active ingredients.

  本发明涵盖了一般式(I)的2,7-二氮杂螺[4.4]壬烷化合物：其中n、X、R2、R3、R4、R5、R6a和R6b如本文所定义，制备所述化合物的方法，用于制备所述化合物的中间化合物，包括所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是癌症或糖尿病，作为唯一药剂或与其他活性成分组合使用。
• [EN] SMALL MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR ACTIVITY AND/OR EXPRESSION AND USES THEREOF<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE L'ACTIVITÉ ET/OU DE L'EXPRESSION DU RÉCEPTEUR DES ANDROGÈNES ET UTILISATIONS CORRESPONDANTES
  申请人：UNIV ARIZONA

  公开号：WO2020123670A1

  公开（公告）日：2020-06-18

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperazine (or similar) structure which function as antagonists of androgen receptor activity, and their use as therapeutics for the treatment of cancer (e.g., castration-resistant prostate cancer) and other conditions characterized with androgen receptor activity and/or androgen receptor expression.

  这项发明属于药物化学领域。具体地说，该发明涉及一类新型小分子，其具有哌嗪（或类似）结构，能够作为雄激素受体活性的拮抗剂，并且它们被用作治疗癌症（例如去势抵抗性前列腺癌）和其他与雄激素受体活性和/或雄激素受体表达相关的疾病的治疗药物。
• SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES
  申请人：Bayer Aktiengesellschaft

  公开号：US20200390100A1

  公开（公告）日：2020-12-17

  The present invention relates to substituted N-heterocyclyl- and N-heteroaryltetrahydropyrimidinones of the general formula (I) or salts thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, and to the use thereof as herbicides, in particular for controlling broad-leaved weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing the growth of crops of useful plants.

  本发明涉及通式（I）或其盐的取代N-杂环烷基和N-杂芳基四氢嘧啶酮，其中通式（I）中的基团对应于描述中给出的定义，并将其用作除草剂，特别是用于控制作物中的阔叶杂草和/或杂草草，并/或作为植物生长调节剂，以影响作物的生长。
• DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST
  申请人：Linders Joannes Theodorus Maria

  公开号：US20110112111A1

  公开（公告）日：2011-05-12

  The present invention relates to combinations of a DGAT inhibitor and a peroxisome proliferator-activator receptor (PPAR) agonist or a prodrug thereof. The invention further relates to methods for preparing such combinations, pharmaceutical compositions comprising said combinations as well as the use as a medicament of said combinations. The present invention also relates to novel DGAT inhibitors. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicament of said compounds.

  本发明涉及一种DGAT抑制剂和过氧化物酶体增殖激活受体（PPAR）激动剂或其前药的组合物。本发明还涉及制备这种组合物的方法，以及包含该组合物的制药组合物和该组合物作为药物的用途。本发明还涉及新型的DGAT抑制剂。本发明还涉及制备这种化合物的方法，以及包含该化合物的制药组合物和该化合物作为药物的用途。
• SUBSTITUTED CYCLOPROPLY COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
  申请人：Edmondson Scott

  公开号：US20140057893A1

  公开（公告）日：2014-02-27

  Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included

  公开了式I的替代环丙基化合物及其药学上可接受的盐，作为治疗或预防2型糖尿病和类似疾病的有用药物。这些化合物可用作G蛋白偶联受体GPR-119的激动剂。还包括药物组合物和治疗方法。